Heart Pump Device - Market Insights, Competitive Landscape, and Market Forecast - 2030

Heart Pump Devices Market Dynamics:

According to the American Heart Association 2022, about 244.1 million people were globally living with coronary (ischemic) heart disease in 2020. As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men. The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.

According to Pan American Health Organization (PAHO) 2022, cardiovascular diseases cause more deaths yearly than any other disease. Heart disease and stroke-related fatalities account for more than three-quarters of all deaths in low- and middle-income nations in 2021.

The increasing number of research and development activities pertaining to heart pump devices is further going to assist in the growth of the heart pump devices market. For example, in August 2022, Abbott based upon data obtained from the MOMENTUM 3 trial announced that its HeartMate 3 heart pump extends the survival of heart failure patients by at least five years.

Therefore, the afore-said factor will propel the overall market of heart pump devices in the upcoming years.

However, the high cost of the pump and low repayment scenario in developing countries may act as a restraint in the growth of the heart pump devices market.

Heart Pump Devices Market Segment Analysis:

Heart Pump Devices by Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product segment of the heart pump devices market, left ventricular assist devices (LVAD) under the ventricular assist devices category are expected to hold the largest share and are one of the fastest-growing segments in this market. It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.

LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation. LVADs are highly reliable and come with built-in safety systems.

Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.

LVADs offer intermediate to long-term treatment solutions for severe heart failure patients.

Hence, all the above-mentioned factors are expected to drive the segment growth of the heart pump devices market.

North America is expected to dominate the overall Heart Pump Devices Market:

North America is expected to dominate the overall Heart Pump Devices market during the forecast period. This can be ascribed to the presence of a large patient pool suffering from cardiovascular diseases (CVDs), the highly potent market in terms of product development and launches, high consumer awareness, and the presence of local key market players among other factors in the country, driving the market growth.

The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.

Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent - the damage is done, but the person is not aware of it.

The increasing number of product development activities in the region is further going to accelerate the growth of the heart pump devices market. For example, in August 2021, the US Food and Drug Administration granted a breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.

Thus, due to the increase in demand for heart pump devices in the region, there will be a subsequent rise in the growth of heart pump devices regional market during the forecast period.

Heart Pump Devices Market Companies:

Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.

Recent Developmental Activities in the Heart Pump Devices Market:

• In August 2021, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed’s Impella ECP expandable percutaneous Heart Pump. The designation means the FDA will prioritize Impella ECP’s regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.
• In February 2021, CARMAT received FDA approval to conduct an Early Feasibility Study (EFS) of its Total Artificial Heart in the US using BlueSync technology.
• In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.

Key Takeaways from the Heart Pump Devices Market Report Study

• Market size analysis for current market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the Global Heart Pump Devices Market.
• Various opportunities are available for the other competitor in the Heart Pump Devices Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Heart Pump Devices market growth in the coming future?

Target Audience who can be benefited from This Heart Pump Devices Market Report Study

• Heart Pump Devices providers
• Research organizations and consulting companies
• Heart Pump Devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders in Heart Pump Devices
• Various End-users want to know more about the Heart Pump Devices Market and the latest technological developments in the Heart Pump Devices market.

Frequently Asked Questions for the Heart Pump Devices Market:

1. What are Heart Pump Devices?

Heart pump devices are utilized in patients that are suffering from heart issues such as a recent cardiac arrest. They carry out the normal functions of the heart by maintaining regular cardiac circulation and replacing the heart partially or completely. After receiving the blood from the heart's lower chambers, it helps transfer the blood to all the vital organs in the body.

2. What is the market for Heart Pump Devices?

Heart Pump Devices Market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030.

3. What are the drivers for Heart Pump Devices?

The major drivers driving the demand for Heart Pump Devices are the increasing prevalence of cardiovascular diseases, the rising geriatric population, and new product development by the market players.

4. What are the key players operating in Heart Pump Devices?

Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.

5. What regions have the highest share in the Heart Pump Devices market?

North America is expected to dominate the overall Heart Pump Devices market during the forecast period, 2024 to 2030. This domination is due to the growing demand for advanced technologies in Heart Pump Devices, the increasing chronic disease in the region is driving the regional growth.


This product will be delivered within 2 business days.